Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates

Perivascular epithelioid cell tumors (PEComas) are a group of rare mesenchymal tumors that typically show both melanocytic and smooth muscle cell features. Some types of PEComa are seen at high frequency in tuberous sclerosis complex (TSC). The TSC1 and TSC2 genes are commonly mutated in both TSC‐associated and sporadic PEComas, and mTOR signaling pathway activation is also common in these tumors. Preliminary reports have indicated that the mTOR inhibitors sirolimus and related drugs have activity in some patients with non‐TSC‐associated PEComa. Here, we report on the use of these medications in the treatment of five consecutive patients with extrarenal nonpulmonary PEComas seen at one institution. Three complete responses, one partial response and one case of progression were seen. Molecular studies identified TSC2 aberrations in four of these patients, and TFE3 translocation was excluded in the resistant case. A review of all published cases as well as those reported here indicates that partial or complete response was seen in 6 of 11 PEComas, with 5 of 6 having a complete response. These findings highlight the consistent though incomplete activity of mTOR inhibitors in the treatment of PEComas.

[1]  P. Argani,et al.  Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. , 2012, The American journal of surgical pathology.

[2]  L. Macconaill,et al.  Angiomyolipoma Have Common Mutations in TSC2 but No Other Common Genetic Events , 2011, PloS one.

[3]  J. Manola,et al.  Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease , 2011, PloS one.

[4]  M. Rubin,et al.  Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  C. Burger.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[6]  K. Pointon,et al.  Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial , 2011, Clinical Cancer Research.

[7]  J. Blay.  Updating progress in sarcoma therapy with mTOR inhibitors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[9]  J. Manola,et al.  Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors , 2010, Clinical Cancer Research.

[10]  M. Ladanyi,et al.  A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions , 2010, The American journal of surgical pathology.

[11]  R. Kurzrock,et al.  Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Bui,et al.  Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Kwiatkowski,et al.  Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics , 2010 .

[14]  C. Antonescu,et al.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Folpe,et al.  Perivascular epithelioid cell neoplasms: pathology and pathogenesis. , 2010, Human pathology.

[16]  H. Lane,et al.  Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis , 2009, Molecular Cancer.

[17]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[18]  C. Pan,et al.  Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma , 2008, The Journal of pathology.

[19]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[20]  G. Zamboni,et al.  PEComas: the past, the present and the future , 2007, Virchows Archiv.

[21]  A. Folpe,et al.  Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. , 2007, Human pathology.

[22]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[23]  Hongbing Zhang,et al.  Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. , 2003, Cancer research.

[24]  Hongbing Zhang,et al.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma , 2003, The Lancet.

[25]  L. Aicher,et al.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. , 2002, Cancer research.

[26]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Scheithauer,et al.  Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. , 1997, The American journal of pathology.